Nanobiotix S.A. ADR (NBTX)

$19.33 +1.63 (9.21%)
Market Cap 848.59M
Revenue (ttm) -7.78M
Net Income (ttm) -73.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 947.69%
Debt to Equity Ratio 0.00
Volume 146,500
Avg Vol 105,088
Day's Range N/A - N/A
Shares Out 47.94M
Stochastic %K 74%
Beta 0.71
Analysts Strong Sell
Price Target $10.95

Company Profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 40 26 04 70
Fax: 33 1 40 26 04 44
Address:
60 rue de Wattignies, Paris, France
PhishTourFunds
PhishTourFunds Nov. 5 at 12:16 AM
$NBTX 🔥
0 · Reply
IsabellaDC
IsabellaDC Nov. 4 at 4:04 PM
$NBTX Swing alert fired.
0 · Reply
PhishTourFunds
PhishTourFunds Nov. 4 at 3:59 PM
$NBTX 💪
0 · Reply
Doozio
Doozio Nov. 1 at 8:00 PM
$NBTX 👀 at that MNDY 🐑 🎁
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 31 at 12:48 PM
$NBTX (+14.2% pre) NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth https://ooc.bz/l/82839
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 31 at 11:16 AM
$NBTX
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 30 at 3:54 PM
$NBTX Morning, fam https://m.youtube.com/watch?v=WILyWmT2A-Q&pp=0gcJCR4Bo7VqN5tD
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 29 at 1:34 PM
$NBTX “Flakes flakes!” https://m.youtube.com/watch?v=cXH5Wy_8BbY
0 · Reply
MorningWoodShow
MorningWoodShow Oct. 28 at 3:58 PM
$WULF $NBTX
0 · Reply
MorningWoodShow
MorningWoodShow Oct. 28 at 3:19 PM
$NBTX time to rise.
0 · Reply
Latest News on NBTX
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Nov 3, 2025, 4:15 PM EST - 1 day ago

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Oct 31, 2025, 3:00 AM EDT - 4 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

Oct 1, 2025, 4:15 PM EDT - 4 weeks ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Sep 30, 2025, 4:15 PM EDT - 5 weeks ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Sep 29, 2025, 6:30 PM EDT - 5 weeks ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Sep 18, 2025, 3:46 PM EDT - 6 weeks ago

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case

Sep 18, 2025, 1:56 PM EDT - 6 weeks ago

Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case

Nanobiotix S.A. - Special Call

Sep 18, 2025, 10:13 AM EDT - 6 weeks ago

Nanobiotix S.A. - Special Call

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Sep 17, 2025, 4:15 PM EDT - 6 weeks ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:15 PM EDT - 2 months ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Jul 7, 2025, 4:15 PM EDT - 4 months ago

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025, 2:00 AM EDT - 5 months ago

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025, 4:15 PM EDT - 5 months ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025, 2:00 AM EDT - 6 months ago

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025, 2:00 AM EDT - 6 months ago

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Apr 30, 2025, 2:00 AM EDT - 6 months ago

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

Apr 3, 2025, 4:24 PM EDT - 7 months ago

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Apr 2, 2025, 4:15 PM EDT - 7 months ago

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Mar 31, 2025, 2:00 AM EDT - 7 months ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Mar 27, 2025, 4:15 PM EDT - 7 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Mar 20, 2025, 4:15 PM EDT - 8 months ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Mar 17, 2025, 4:15 PM EDT - 8 months ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Jan 29, 2025, 4:15 PM EST - 9 months ago

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Jan 21, 2025, 2:30 AM EST - 10 months ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Dec 17, 2024, 4:15 PM EST - 11 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Dec 9, 2024, 4:15 PM EST - 11 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Nov 12, 2024, 2:30 AM EST - 1 year ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Oct 31, 2024, 3:30 AM EDT - 1 year ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 18, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 4, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 12, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Jun 2, 2024, 10:00 AM EDT - 1 year ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 28, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

May 22, 2024, 8:32 PM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

May 22, 2024, 2:00 AM EDT - 1 year ago

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

May 21, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

May 15, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

May 14, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Apr 27, 2024, 11:51 AM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Apr 24, 2024, 4:40 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Apr 17, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Apr 2, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Nanobiotix to Present at Upcoming Investor Conferences in March

Mar 6, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at Upcoming Investor Conferences in March

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Jan 31, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Jan 29, 2024, 4:15 PM EST - 1 year ago

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 1:01 PM EST - 2 years ago

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Nov 9, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

PhishTourFunds
PhishTourFunds Nov. 5 at 12:16 AM
$NBTX 🔥
0 · Reply
IsabellaDC
IsabellaDC Nov. 4 at 4:04 PM
$NBTX Swing alert fired.
0 · Reply
PhishTourFunds
PhishTourFunds Nov. 4 at 3:59 PM
$NBTX 💪
0 · Reply
Doozio
Doozio Nov. 1 at 8:00 PM
$NBTX 👀 at that MNDY 🐑 🎁
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 31 at 12:48 PM
$NBTX (+14.2% pre) NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth https://ooc.bz/l/82839
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 31 at 11:16 AM
$NBTX
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 30 at 3:54 PM
$NBTX Morning, fam https://m.youtube.com/watch?v=WILyWmT2A-Q&pp=0gcJCR4Bo7VqN5tD
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 29 at 1:34 PM
$NBTX “Flakes flakes!” https://m.youtube.com/watch?v=cXH5Wy_8BbY
0 · Reply
MorningWoodShow
MorningWoodShow Oct. 28 at 3:58 PM
$WULF $NBTX
0 · Reply
MorningWoodShow
MorningWoodShow Oct. 28 at 3:19 PM
$NBTX time to rise.
0 · Reply
MorningWoodShow
MorningWoodShow Oct. 28 at 1:57 PM
$NBTX In fast, out faster. I don’t marry dips, I just date ‘em for profits.
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 28 at 11:10 AM
$NBTX 💪
0 · Reply
PhishTourFunds
PhishTourFunds Oct. 28 at 4:57 AM
$NBTX ~50% retracement from the crazy run to $30 = buy signal
0 · Reply
Team_Zissou
Team_Zissou Oct. 21 at 10:25 PM
$NBTX No position here, but started monitoring the stock a month ago. Seems like the last two weeks have had a double gig it swing each day on no news. Anyone know why it has so much volatility? Is it just low volume?
1 · Reply
BambooC
BambooC Oct. 13 at 6:17 PM
$LKNCY $NBTX $SUPX
0 · Reply
BambooC
BambooC Oct. 13 at 6:16 PM
$LKNCY $NBTX
1 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:51 PM
Keep a close watch on CMCT! $CART $AAP $AMTX $NBTX //
0 · Reply
Doozio
Doozio Oct. 9 at 12:43 AM
$NBTX obviously
0 · Reply
History101
History101 Oct. 8 at 11:47 PM
$NBTX 476 watching 10/8/2025
0 · Reply
tommy_john
tommy_john Oct. 8 at 1:58 PM
$NBTX is this trading?
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 7:42 AM
$NBTX Great piece that accurately captures NBTX's current position. So if you want to refresh your understanding of NBTX or learn about NBTX for the first time, this is essential reading. https://beyondspx.com/quote/NBTX/analysis/nanobiotix-unlocking-oncology-s-future-with-physics-based-therapies-and-a-de-risked-partnership-nasdaq-nbtx
0 · Reply
MTRADe_01
MTRADe_01 Oct. 2 at 7:17 PM
$NBTX biotech mover, >22 with RVOL = entry $GRPN meme angle, scalp only with momentum $BYND still crowded short, treat as quick trade Follow if you want more squeeze watchlists daily 🙌
0 · Reply